Machine learning prioritizes agonists for two human olfactory receptors
A random-forest classifier trained from molecular descriptors screened five databases containing about 23 million compounds for agonists of human olfactory receptors OR1A1 and OR2W1. Following docking and researcher selection, the paper reports in-vitro activation by ethyl 2-(3-bromophenyl)acetate and methyl 2-(2-methylphenyl)acetate at OR1A1 and 2-ethoxynaphthalene at OR2W1. These are cell-assay results; they do not establish human perception, tissue safety or clinical benefit. The compounds were selected after multiple filters, so the results are not a database-wide hit rate. Prior ML work on related receptors exists; this record is limited to the reported candidates and assays.
Technology: Random-forest classifier; molecular descriptors; homology-model docking
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Selected candidates were tested in vitro; the paper reports two active OR1A1 ligands and one active OR2W1 ligand.
- Still unknown: No in-vivo human olfaction or clinical effect is established. A 2018 study used ML for related human receptors; candidate-level overlap and priority remain bounded follow-up.
- AI role: The random-forest classifier screened chemical databases to rank candidates; docking and researcher selection further narrowed compounds for in-vitro validation.
Evidence sources: https://www.mdpi.com/1422-0067/22/21/11546
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: Primary publisher article, article metadata and author-affiliation block reviewed; summary is limited to reported assay results..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.